Farmaprojects/Polpharma Group, in collaboration with its partners, has successfully launched Dapagliflozin film-coated tablets in the United Kingdom. As a major diabetes and cardiovascular treatment, the launch represents an important step in addressing two of the most pressing global health challenges.
This achievement exemplifies Farmaprojects’ strategic ‘patient-first’ approach, driving better health outcomes and expanding patient access. The introduction of Dapagliflozin to the UK market reflects the dedication of all internal and external teams who worked relentlessly to overcome significant uncertainties and risks. This success story demonstrates the strength of collaboration across our network, combining expertise, resilience, and a clear focus on patient needs. By ensuring timely access to an effective therapy, Farmaprojects reinforces its commitment to delivering innovative and reliable solutions that improve quality of life.
Launching first in the UK marks the starting point in our exploration of broader European expansion, subject to the legal frameworks in each market. This reflects our strategic focus on overcoming IP challenges and securing early market access. The Dapagliflozin launch is a strong demonstration of Farmaprojects’ ability to anticipate market needs and respond with agility. We are a trusted partner, capable of delivering complex projects with precision and speed.
At Farmaprojects, we believe that progress in healthcare is only possible when patients come first. This launch is another step forward in our mission to enable better treatments, greater access, and improved outcomes.
Yes You Health.